How is tirzepatide dosed?

What tirzepatide is

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, manufactured by Eli Lilly. It has two FDA-approved labels, each covering different indications: Mounjaro (type 2 diabetes) and Zepbound (weight reduction and obstructive sleep apnea, without a type 2 diabetes requirement). Both share the same active ingredient and the same manufacturer, but each label sets its own dosing schedule, cites its own trials, and carries its own adverse-event table — reading either one alone gives an incomplete picture of how the compound is actually dosed across both approved uses.

Prof. Peptide has already read each label in full detail on its own page — how Mounjaro is dosed and how Zepbound is dosed. This page exists to put them side by side, which neither brand page nor the tirzepatide profile currently does in one table.

Mounjaro vs. Zepbound: the label schedules, compared

Eli Lilly, MOUNJARO (tirzepatide) injection prescribing information, DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective August 27, 2026; Eli Lilly, ZEPBOUND (tirzepatide) injection prescribing information, DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective August 28, 2026. Each brand’s own adverse-event figures below are placed directly under that brand’s dosage table, at its own maximum dose, rather than in a separate section.

The escalation mechanics match — both labels start at 2.5 mg once weekly and increase in 2.5 mg increments after at least 4 weeks per step, both cap at 15 mg once weekly for adults. What differs is what each label does with that mechanism: Mounjaro describes one escalation path toward a single adult maximum (with a separate 10 mg pediatric maximum the Zepbound label does not carry at all, since Zepbound has no pediatric indication), while Zepbound sets distinct maintenance dosage options by indication rather than one target dose. Both share the identical 4-day (96-hour) missed-dose window and the same dosage forms and strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg per injection) — both labels state these as four separate presentations at those same per-injection strengths (single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens, the multi-dose vial and KwikPen each holding 4 doses at a higher total concentration than the single-dose forms), with no reconstitution math in either document.

Trials that add something neither label states

Each label cites its own trial program — SURPASS for Mounjaro, Study 1 through Study 5 (publicly known as SURMOUNT) for Zepbound. Two published trials sit outside both labels entirely and answer questions neither one does:

Is there a research-grade dosing standard?

The tirzepatide profile states: “Prof. Peptide has not identified a sourced research-grade dosing convention that differs from or matches either label.” That is an explicit statement of absence, not a claim that research-grade dosing mirrors the approved schedule.

Checked for a genuinely sourceable research-grade or community dosing convention distinct from the two labels’ own schedules above and did not find one — no vendor page, forum consensus, or published source reports a tirzepatide protocol that differs from what Mounjaro’s and Zepbound’s own labels already specify. That absence is reported here, consistent with the profile’s own statement, rather than treated as license to assert that research-grade dosing mirrors the label as independently verified fact.

Compounding and research-grade tirzepatide

Separately from either branded label, FDA has published its own position on compounded tirzepatide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.

On April 30, 2026, FDA announced it is proposing to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.

None of this changes what either label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here, at the compound level rather than under either brand alone, because a reader comparing research-grade tirzepatide against the approved product should see, in one place, that both labels are governed by different rules from the research-grade material, and that the regulatory status of compounded tirzepatide is itself unsettled.

How this page differs from the brand guides and the profile

How Mounjaro is dosed and how Zepbound is dosed each read one label in full depth — a complete escalation table, boxed warning quoted verbatim, and a full adverse-reaction table by dose, with a standalone warnings section. Neither compares its own figures against the other brand’s in a table; each treats the other only in passing, in its own “how this page differs” section. This page is the one place both schedules, both missed-dose windows, and both boxed-warning wordings sit in the same table, with adverse events placed next to each brand’s own dose rather than in a separate section.

The tirzepatide profile is a different kind of page again: it covers the molecule’s mechanism and the published trial evidence across both brands and beyond (cardiovascular outcomes, heart failure), without reading either label’s escalation table, missed-dose rule, or ADR table in the detail either brand guide or this page does. This page exists because comparing Mounjaro’s and Zepbound’s dosing schedules directly — the specific figures that differ between them — is not something the profile’s FAQ-level summary or either brand guide’s single-label read currently does in one place.

Related pages

How Mounjaro is dosed and how Zepbound is dosed each read one label in full. The tirzepatide profile covers the mechanism and the broader trial evidence. The tirzepatide reconstitution calculator performs the vial-strength-to-concentration arithmetic for research-grade material across the sizes Prof. Peptide tracks — neither label needs this arithmetic, since both describe a pre-filled pen or vial, not a lyophilized powder. SURMOUNT-5, cited above, compares tirzepatide directly against semaglutide — see how semaglutide is dosed for the same head-to-head trial read from semaglutide’s side, alongside Ozempic’s and Wegovy’s own label schedules.

FAQ

References

1. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information. DailyMed, setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information. DailyMed, setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. ClinicalTrials.gov NCT05822830. https://clinicaltrials.gov/study/NCT05822830
4. ClinicalTrials.gov. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4), NCT04660643. https://clinicaltrials.gov/study/NCT04660643
5. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
6. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list